Coherus BioSciences (NASDAQ:CHRS) Given Buy Rating at HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $7.00 price objective on the biotechnology company’s stock.

A number of other equities analysts also recently commented on CHRS. UBS Group reissued a “neutral” rating and set a $1.05 price objective (down from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. StockNews.com cut shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Coherus BioSciences currently has an average rating of “Hold” and an average target price of $5.26.

Coherus BioSciences Stock Up 3.0 %

Coherus BioSciences stock opened at $1.03 on Tuesday. Coherus BioSciences has a 52-week low of $0.66 and a 52-week high of $2.43. The firm has a market cap of $119.37 million, a PE ratio of -12.88 and a beta of 1.01. The company’s 50 day moving average is $0.96 and its two-hundred day moving average is $1.12.

Institutional Trading of Coherus BioSciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new position in shares of Coherus BioSciences in the fourth quarter valued at approximately $34,000. Steph & Co. acquired a new position in Coherus BioSciences in the 4th quarter valued at $34,000. Intech Investment Management LLC purchased a new position in Coherus BioSciences during the 4th quarter worth $38,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Coherus BioSciences by 97.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 15,214 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Coherus BioSciences by 84.0% in the 1st quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 24,953 shares during the period. 72.82% of the stock is owned by institutional investors and hedge funds.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.